Edition:
United Kingdom

Aevi Genomic Medicine Inc (GNMX.OQ)

GNMX.OQ on NASDAQ Stock Exchange Global Market

1.16USD
4:02pm GMT
Change (% chg)

$-0.02 (-1.69%)
Prev Close
$1.18
Open
$1.18
Day's High
$1.20
Day's Low
$1.15
Volume
11,445
Avg. Vol
59,519
52-wk High
$6.89
52-wk Low
$0.98

Latest Key Developments (Source: Significant Developments)

Aevi Genomic Medicine Files For Resale Of Up To 26.2 Mln Shares Of Co's Common Stock By Selling Stockholders
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Aevi Genomic Medicine Inc ::AEVI GENOMIC MEDICINE INC FILES FOR RESALE OF UP TO 26.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Aevi Genomic Medicine Q3 loss per share $0.23
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Aevi Genomic Medicine Inc ::Aevi Genomic Medicine reports third quarter 2017 financial results.Q3 loss per share $0.23.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Aevi Genomic Medicine Inc - ‍company had cash and cash equivalents of $14.96 million at September 30, 2017​.Aevi Genomic Medicine Inc- ‍expects current cash balance, including proceeds from pipe offering, to fund operations into early 2019​.  Full Article

Medgenics announces public offering of common stock
Monday, 20 Jun 2016 

Medgenics Inc : Medgenics announces public offering of common stock . Medgenics Inc says intention to offer and sell shares of its common stock in an underwritten public offering .Medgenics Inc says net proceeds to be used for product development activities, including development of companion diagnostics for existing programs.  Full Article

Medgenics enters collaboration with Kyowa Hakko Kirin
Monday, 6 Jun 2016 

Medgenics Inc : Entered collaboration with Kyowa Hakko Kirin Co Ltd for development and commercialization of Kyowa Hakko's anti-light monoclonal antibody . Data from signal finding study in severe pediatric onset inflammatory bowel disease patients expected in first half 2017 . Upon completion of signal finding study in severe pediatric onset IBD, company will have option to license rights to develop program . Following exercise of option, medgenics will make a one-time, upfront payment in low single-digit millions to Kyowa Hakko Kirin .Co to have commercialization rights in U.S., Canada, will also add rights in europe if Kyowa Hakko Kirin selects licensing arrangement.  Full Article

Medgenics Q1 loss per share $0.34
Tuesday, 10 May 2016 

Medgenics : Reports First Quarter 2016 Financial Results And Nfc-1 program update . Q1 loss per share $0.34 .Q1 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Medgenics, Inc promotes Brian Piper to CFO
Wednesday, 3 Feb 2016 

Medgenics, Inc:Promotes brian piper to chief financial officer.Says john leaman, co's current CFO, will be leaving the company effective February 9, 2016 to pursue other interests.  Full Article

BRIEF-Aevi Genomic Medicine Files For Resale Of Up To 26.2 Mln Shares Of Co's Common Stock By Selling Stockholders

* AEVI GENOMIC MEDICINE INC FILES FOR RESALE OF UP TO 26.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text - http://bit.ly/2kEddlX Further company coverage: